Stocks›Healthcare›MDXG

MDXG

MiMedx Group, Inc.

NasdaqResearch view

HealthcareSurgical & Medical Instruments & ApparatusSmall-capSEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$686.5M

Enterprise Value$539.9M

Income$48.6M

Sales$418.6M

Book/sh$1.76

Cash/sh$1.14

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.92

Current Ratio4.32

Debt/Eq0.08

EPS (ttm)$0.32

EPS this Y14.3%

EPS past 3/5Y—

Sales past 3/5Y16.1%

EPS Y/Y TTM14.3%

Sales Y/Y TTM20.0%

Shs Outstand145.76M

ROA14.2%

ROE18.9%

ROIC42.6%

Gross Margin82.6%

Oper. Margin15.3%

Profit Margin11.6%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

$242.0M

2021

$267.8M

2022

$321.5M

2023

$348.9M

2024

$418.6M

2025

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$242.0M	$267.8M	$321.5M	$348.9M	$418.6M
Gross Profit	$202.4M	$219.5M	$266.8M	$288.8M	$345.6M
Operating Income	$-7.1M	$-14.7M	$37.1M	$58.9M	$63.9M
Net Income	$-10.3M	$-30.2M	$58.2M	$42.4M	$48.6M
Diluted EPS	$-0.15	$-0.33	$0.37	$0.28	$0.32
Operating Cash Flow	$-2.0M	$-17.9M	$26.8M	$66.2M	$74.0M
Free Cash Flow	$-5.2M	$-19.4M	$24.8M	—	—

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Cash-flow detail unavailable in this filing.

—

Follow the news. Track the move.

MDXG story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Sep 23

Court vacates FDA rulings on MiMedx’s AXIOFILL classification

A court vacated FDA rulings concerning MiMedx’s AXIOFILL classification. The decision reopens the regulatory path for the product, with its commercial implications dependent on the next FDA and court steps.

Price history unavailable

Investing.com · 1d ago

View both sides →

Follow the news. Track the move.